Missense and Loss of Function Variants at GWAS Loci in Familial Alzheimer's Disease

Tamil Iniyan Gunasekaran, PhD[1], Dolly Reyes-Dumeyer, BS[1], Kelley M. Faber, MS[2], Alison Goate, DPhil[3], Brad Boeve, MD[4], Carlos Cruchaga, PhD[5], Margaret Pericak-Vance, PhD[6], Jonathan L. Haines, PhD[7], Roger Rosenberg, MD[8], Debby Tsuang, MD[9], Diones Rivera Mejia, MD[10,11], Martin Medrano, MD[12], Rafael A. Lantigua, MD[1,13], Robert A. Sweet, MD[14], David A. Bennett, MD[15], Robert S. Wilson, PhD[15], Camille Alba, MS[16], Clifton Dalgard, PhD[16], Tatiana Foroud, PhD[2], Badri N. Vardarajan, PhD[1*], Richard Mayeux, MD[1*]

Affiliations:

[1]Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H. Sergievsky Center, Columbia University, 630 West 168th St., New York, NY, 10032 USA

[2]Department of Medical and Molecular Genetics, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), 410 W. 10th St., HS 4000. Indiana University School of Medicine, Indianapolis, IN, 46202-3002, USA

[3]Department of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, Icahn Bldg., One Gustave L. Levy Place, New York, NY, 10029, USA

[4]Department of Neurology, Mayo Clinic, 200 1st St SW Floor 16, Rochester, MN, 55905, USA

[5]Department of Psychiatry, Washington University in St. Louis, Rand Johnson Building, 600 S Euclid Ave, Wohl Hospital Building, St. Louis, MO, 63110, USA

[6]John P Hussman Institute for Human Genomics, Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, PO Box 019132 (M-860) Miami, FL, 33101, USA

[7]Department of Population & Quantitative Health Sciences and Cleveland Institute for Computational Biology. Case Western Reserve University, 10900 Euclid Ave. Cleveland, OH, 44106-7288, USA

[8]Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA

[9]Department of Psychiatry and Behavioral Sciences, University of Washington, GRECC VA Puget Sound, 1660 South Columbian Way, Seattle WA, 98108, USA

[10]Los Centros de Diagnóstico y Medicina Avanzada y de Conferencias Médicas y Telemedicina, CEDIMAT, Arturo Logroño, Plaza de la Salud, Dr. Juan Manuel Taveras Rodríguez, C. Pepillo Salcedo esq, Santo Domingo, Dominican Republic

[11]Universidad Pedro Henríquez Urena, Av. John F. Kennedy Km. 7-1/2 Santo Domingo 1423 Santo Domingo, Dominican Republic

[12]Pontíficia Universidad Católica Madre y Maestra (PUCMM), Autopista Duarte Km 1 1/2, Santiago de los Caballeros 51000, Dominican Republic

[13]Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, 630 West 168th Street, New York, NY, 10032 USA

[14]Departments of Psychiatry and Neurology, University of Pittsburgh, 3471 Fifth Ave. # 811, Pittsburgh, PA, 15213, USA

[15]Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 West Harrison St. Chicago, IL, 60612, USA

[16]Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge RD, Bethesda, MD, 20814, USA

* Contributed equally to the manuscript.

Correspondence:
Richard Mayeux, MD
Columbia University
710 West 168th Street
New York, NY 10032
(T) 212 305-2391
Email: rpm2@cumc.columbia.edu

Abstract

BACKGROUND. Few rare variants have been identified in genetic loci from genome wide association studies of Alzheimer's disease (AD), limiting understanding of mechanisms and risk assessment, and genetic counseling.

METHODS. Using genome sequencing data from 197 families in The NIA Alzheimer's Disease Family Based Study, and 214 Caribbean Hispanic families, we searched for rare coding variants within known GWAS loci from the largest published study.

RESULTS. Eighty-six rare missense or loss of function (LoF) variants completely segregated in 17.5% of families, but in 91 (22.1%) of families *APOE-e4* was the only variant segregating. However, in 60.3% of families neither *APOE-e4* nor missense or LoF variants were found within the GWAS loci.

DISCUSSION. Although *APOE-ε4* and several rare variants were found to segregate in both family datasets, many families had no variant accounting for their disease. This suggests that familial AD may be the result of unidentified rare variants.

1. BACKGROUND

In the United States (US) in 2023, Alzheimer's disease (AD) was present in 6.7 million people, representing 10.8% of the population over age 65 years, and is projected to grow to 13.8 million people, nearly 3.3% of the total US population by 2060.[1] The cause(s) of AD remain elusive, but there is strong evidence that it is a polygenic disorder. Highly penetrant pathogenic variants in AD: *APP*[2; 3] *PSEN1*[4] and *PSEN2*[5] explain less than 5% of early-onset familial AD (fAD). The *APOE-ε4* allele is associated with the risk of developing late onset, sporadic AD,[6; 7] and has been replicated in most ethnic groups.

Late-onset sporadic AD is highly heritable (~70%), implying that genetic factors contribute to its etiology. The largest genome wide association studies (GWAS) that included thousands of unrelated individuals with AD and non-demented controls led by the European Alzheimer and Dementia Biobank Consortium, the UK Biobank, the Alzheimer's Disease Genetic Consortium, the Alzheimer's Disease Sequencing Project, FinnGen and CHARGE Consortia, identified common variants in more than 75 genetic risk loci. None of these risk loci reaches the effect size of *APOE-ε4*[8].

The goal of this investigation was to identify rare variants associated within the 75 genetic loci in late-onset familial AD (fAD). We chose to limit the age at onset to later than 65 years to distinguish the study population from those with early-onset familial AD. This approach would allow us to estimate the proportion of families where the diagnosis of AD could be "explained" by genes identified by common variants in GWAS loci. Family-based statistical tests are largely underpowered to detect rare variants in novel genes with a limited number of family members and little or no evidence of vertical transmission. Thus, we used a simple segregation analysis restricted to genes that were previously associated with AD in GWAS.

There are clear advantages to family-based studies. Family-based analyses reduce the effects of population stratification, allow for easier detection of Mendelian inconsistencies and accurate haplotype phasing, and can detect the parent-of-origin effects. Investigation of well-characterized and carefully selected families can result in the identification of rare variants with significant roles in the pathogenesis of familial AD.[9]

One of the most frequent questions posed by family members of patients with fAD concerns familial risk. Polygenic risk scores have recently been used to assess recurrence risk and penetrance in families.[10]However, identification of pathogenic variants in fAD, would advance mechanistic and therapeutic research efforts and facilitate genetic counseling. To identify and determine the frequency of potentially pathogenic variants in fAD, we used genome sequencing data from families recruited in the US and the Dominican Republic to identify damaging missense and loss of function (LoF) variants in candidate genes nominated from the largest GWAS analyses of clinically and pathologically diagnosed AD.[8]

2. METHODS

2.1 Inclusion Criteria and Ethical Review. We required first-degree family members, typically siblings, as the primary criterion[11]. The criteria for study entry included two living affected (clinically demented or cognitively symptomatic) siblings, 60 years of age or older, and a third living relative, similar in age, with or without dementia. We also included families with deceased affected siblings, as long as autopsy information or frozen brain tissue was available for affected members. Families in which participants were symptomatic, but did not meet criteria for AD, were still included with the commitment for follow-up. Details of the recruitment for both cohorts have been previously described[11-13]. Recruitment protocols underwent ethical review at each site and were consistent across all sites in the NIA AD-FBS. In the Dominican Republic there was a central review board for the EFIGA study following the review at Columbia University. Women and men were included. There were no

exclusions based on ethnic group or race because this was a family-based study that investigated family-specific rare variants.

2.2 National Institute on Aging AD Family-Based Study (AD-FBS). Beginning in 2002, families were recruited from Alzheimer's Disease Centers across the United States. Inclusion criteria for this study required one member to have a diagnosis of definite or probable AD[14]with onset after age 60 and a sibling with definite, probable, or possible AD and a similar age at onset. Another relative of the affected sibling pair, 60 years of age or older if unaffected, or if affected diagnosed with AD, was required. Any relatives over age 50 years were also recruited, regardless of cognitive status, but individuals deemed unaffected were required to have had documented cognitive testing and clinical examination. Most sites used a standard neuropsychological batter including Logical Memory (Immediate and Delayed), Selective Reminding Task, Orientation (MMSE), Digit Span Forward and Backward, Digit Ordering, Category Fluency (animals and vegetables)[11]. Every participant provided informed consent. Demographic information, previous clinical diagnoses, age at onset for patients with AD, method of diagnosis, Clinical Dementia Rating Scale[15]was ascertained. The age at onset for participants was defined as the age at which the family first observed signs of impaired cognition. For unaffected family members, we used their age at the time of their latest examination without impairment. Participants with advanced disease or those living in a remote location that could not complete a detailed in-person evaluation, contributed a blood sample, and the site investigator conducted a detailed review of medical records or an assessment by telephone or videoconference to document the presence or absence of AD. We used the NINCDS-ADRDA criteria[14] for definite AD or pathological criteria for AD[16; 17] when based on postmortem information alone. Individuals with other forms of dementia, mild cognitive impairment or uncorroborated family reports of AD were considered as unaffected. From a pool of 251 families with 1,055 individuals, we restricted the selection to families with two or more affected family members by clinical or pathological diagnosis, which yielded 197 families with 926 individuals and WGS data. There were 545 (58.8%) individuals with fAD and 381 individuals without dementia. The mean age at onset was 75.2 (s.d.8.04)

years of age and they were white, non-Hispanic. Those affected were significantly older than those unaffected (Table 1a). The majority of families were white, and of non-Hispanic ancestry. There were approximately 12 families of African American ancestry.

2.3 Estudio Familiar de la Influencia Genética en Alzheimer (EFIGA) cohort. We acquired data from a second set of families with late onset fAD from the EFIGA cohort to identify variants segregating among families of Caribbean Hispanic ancestry. Study design, adjudication, and clinical assessment of AD in this cohort was previously described[12; 18] and similar to that used in the AD-FBS. The neuropsychological batter for EFIGA included the Selective Reminding Test, Benton Recognition, Orientation (from MMSE), Abstract Reasoning (similarities and identities/oddities), Naming (Boston Naming Test), Verbal Fluency "CFL", Category Fluency (animals), Repetition, Comprehension, Benton Matching, Attention, and Literacy[12,18]. All individuals provided informed consent. Participants were followed every two years and evaluated using the same neuropsychological battery, structured medical and neurological examination, assessment of depression,[19]The Clinical Dementia Rating Scale,[15]and the research clinical diagnosis of AD was determined. There were 271 families with 1,481 individuals but restricting the selection of families to those with two or more affected family members, 214 (78.9%) families remained with 1,340 individuals with available genome sequencing. There were 793 (59.2%) individuals who met criteria for clinical fAD and 547 individuals without dementia. The mean age of onset was 71.2 years (s.d.9.9). Those affected were significantly older that those unaffected (Table 1b). All of the individuals included with of Caribbean Hispanic ancestry.

2.4 Whole Genome Sequencing. The genome sequencing at the New York Genome Center and at the Uniformed Services University of the Health Sciences using one microgram of DNA, an Illumina PCR-free library protocol, and sequenced on the Illumina HiSeq platform. We assessed sex mismatches and unexpected familial relationships prior to analyses. We harmonized the WGS from the two sites in the EFIGA and AD-FBS families, and jointly called variants to create a uniform, analysis set. Genomes

were sequenced to a mean coverage of 30x. Sequence data analysis was performed using an automated analysis pipeline that matched the CCDG and TOPMed recommended best practices.[20] Briefly, sequencing reads were aligned to the human reference, hs38DH, using BWA-MEM v0.7.15. Variant calling was performed using the GATK best-practices. Variant filtration was performed using Variant Quality Score Recalibration (VQSR at tranche 99.6%) which identified annotation profiles of variants that could be called with high confidence and assigns a score (VQSLOD) to each variant. Variants passing the VQSR threshold were further filtered out for sample missingness (>2%), depth of coverage-DP<10 and genotype quality-GQ>20. We then annotated high quality variants using ANNOVAR. Specifically, variants were annotated for population level frequency using Genome Aggregation Database (gnomAD), *in-silico* function using Variant Effect Predictor (VEP) and variant conservation using Combined Annotation Dependent Depletion score (CADD).

2.5 Segregation analysis and identification of damaging missense and loss of function variants. The search was limited to variants in genetic loci identified in the largest GWAS where individuals were clinically or pathologically examined.[8]This analysis included cohorts such as UK Biobank where AD diagnosis was ascertained by proxy or family history. We also searched genes involved in early onset fAD: *APP, PSEN1 and PSEN2*, and *AKAP9.* The total number of genes or loci queried was 81 (Supplementary Table 1). Segregation of variants was defined by presence in all affected family members and in an unaffected family member if they were at least five years younger than the mean age of onset of AD in the family. Damaging coding variants were prioritized: loss of function (LoF) variants (stoploss, stopgain, frameshift or splice variants) or damaging missense with a high CADD >20. Only variants considered rare in the general population (less that 1% in gnomAD) were included. The high allelic frequency of *APOE-ε4* in the general population and in AD, required examination of the co-segregation within families with and without a segregation of damaging missense or LoF variants. Linkage Disequilibrium (LD) computation: We computed LD between the statistically significant common variant

at each loci reported [8]and segregating rare variant using PLINK. We report the r^2 between the variants as a measure of LD.

3.0 RESULTS

There were a combined 522 families with 2,535 individuals sequenced in the two datasets. After excluding families with less than two affected family members there remained 411 families with 2,266 individuals in the two datasets. In the AD-FBS, 926 individuals (58.9%) met criteria for definite or probable fAD (19.6% vs 80.4%, respectively) and the remaining family members were unaffected. In EFIGA, there were 1,340 individuals in this family group, of which 59.1% met criteria for probable fAD and the remaining individuals were considered unaffected. Other demographics provide age at recruitment, age at onset and sex (Tables 1a & 1b).

3.1 Presence of damaging missense and LoF variants*.* We identified 4,749 total coding variants in 81 candidate genes and loci within the two cohorts (Supplementary table 1). We restricted the search to damaging potentially pathogenic coding variants using LoF variants or missense variants with CADD score greater than 20 (Figure 1). Forty-six damaging coding variants or loss of function variants were identified in 32 genes among 38 white, non-Hispanic families in AD-FBS. In the EFIGA there were 40 coding variants in 32 genes segregating in 34 families. *ABCA1, AKAP9, ANK3, NYO15A, and SLC26A1* contained the highest number of variants. No damaging missense variant was present in both family datasets, but a rare LoF frameshift variant in *ABCA7*, (Ch19:1044708, GGGGCACCTGGT:G) was present in the AD-FBS and EFIGA datasets. A full list of the coding variants in both family datasets are provided in Table 2. Variants in 20 genes were also found in the case-control series from the Alzheimer's Disease Sequencing Project (Supplementary Table 2). Over 100 damaging missense or LoF variants in the AD-FBS and in the EFIGA families showed incomplete segregation in families (Supplementary Table 3).

3.2 *APOE* co-segregation. *APOE-ε4* co-segregated with LoF variants in *ABCA1, DOC2A*, and SLC26A1/IDUA in four of the white, non-Hispanic families, but there was no co-segregation in Hispanic families with any LoF variant. Missense variants in nine genes co-segregated with *APOE-ε4* including: *ABCA1, AKAP9, ANK3, CTSB, EED, PRDM7, SNX1, USP6NL, WDR81* in the AD-FBS families, while in the EFIGA families *APOE-ε4* segregated with missense variants in *ADAMTS20, AKAP9, ANK3, CR1, SORL1* and *TSPOAP1.* The presence of *APOE ε4* did not affect age at onset of dementia (Table 3). *APOE-e4* was the only variant segregating 93 (22.6%) of families, Among the AD-FBS cohort, 64 (32.5%) families had only segregation with *APOE-ε4*, and in the EFIGA cohort, 29 (13.5%) families had only *APOE-ε4* segregation.

3.3 Linkage disequilibrium (LD) between common and rare variants. Thirty-three (43.4%) of the 76 damaging missense variants or LoF variants were in linkage disequilibrium with the most significant common variant from the GWAS[8]or with any of the four other candidate genes. Because LD is sensitive to allele frequency, we anticipated that the likelihood of a common and rare variant being in LD would be very low. Thus, we also investigated whether the most significant common variant from the GWAS data co-segregated with any rare variant we identified. Within AD-FBS families, we identified one LoF variant in *RBCK1* and ten damaging missense variants that co-segregated with the common variant (Table 3). Within EFIGA families, 15 damaging missense variants and one LoF variant completely co-segregated with the common variants (Table 3).

In 64 (32.5%) of the AD-FBS families and 29 (13.6%) of the EFIGA families, there were no segregating variants in any of the GWAS loci and *APOE-ε4* was the only risk allele segregating in these families. Among the AD-FBS cohort, 99 (50.3%) families had no rare variants identified and were not found to have *APOE-ε4* accounting for the segregation within the families. Similarly, 149(69.6%) of the EFIGA families had no rare variants identified and did not have *APOE-ε4* segregation.

4.0 DISCUSSION

Using existing data from whole genome sequencing in two groups of families multiply affected by late onset fAD we identified rare, potentially pathogenic, segregating variants embedded in or near risk loci reported from a large GWAS of unrelated individuals[8], present in Mendelian forms of early onset fAD,[2-5]or identified by small sequencing investigations (e.g. *AKAP9).*[21]We found numerous coding variants prior to restricting the analyses to damaging missense variants and LoF variants at these loci. In 38 AD-FBS families, variants in 29 genes were identified as fully segregating in all affected family members and younger relatives at risk (Table 3). Similarly, in 34 EFIGA families, variants in 31 genes were observed segregating. The highest frequency of segregating variants was found in *ABCA1, AKAP9, ANK3, MYO15A, and SLC26A1* in both groups of families. We also found no segregating variants within the GWAS loci and no evidence of *APOE-ε4* segregation in 60.3% of the families. This clearly indicates that an unbiased search for additional pathogenic variants, including structural variants should be undertaken to fully explain the genetic basis of fAD.

Genome wide array studies were designed using common genetic variation across the genome to identify loci that are associated with a trait or disease. Most are common variants that confer small effects regarding the proportion of the trait or disease risk. Rare variants are defined by allele frequency of less than 0.01. This is an arbitrary criterion, but it is well-accepted in the field and based on the observed effect sizes for variants at different MAF thresholds.[22]Rare variants generally have a larger effect size compared with common variants, and they are more suitable for functional genomic and mechanistic analyses investigating them as potential drug targets. They can also be used for genetic counseling or as putative biomarkers to support a personalized medicine.[23]

Determining whether the rare variants identified in these two cohorts were in LD with the common variants from the GWAS loci can be difficult because the much higher frequency of the significant

common variant compared with the rare variant. As an alternative we determined the frequency by which the significant common variant in the GWAS co-segregated with the rare variant. Among the AD-FBS families one (10%) LoF variants and 10 (41.7%) missense variants co-segregated with the significant common variant, compared with 2(66.7%) LoF variants and 16 (57.1%) missense variants co-segregated with the significant common variant in EFIGA families (Table 2).

Rare variants were found in *ABCA1, AKAP9,* and *ABCA7* which are well established as genes involved in AD. A variant in *ABCA1*, an ATP-binding cassette transporter A1, was identified in a large exome sequencing study[24] of AD, and associated with reduced ApoE levels and decreased clearance of Aβ.[25] This specific variant was not observed in the family data but several rare variants in *ABCA1* co-segregated with chr9: 104794495 (Table 3). Rare variants in A-kinase anchoring protein 9, *AKAP9*, were described in a small cohort of black, non-Hispanic individuals.[21] Subsequently, a rare variant (p.Arg434Trp) was observed in two large families from the Dominican Republic.[13] *AKAP9* contains 51 exons and is a binding protein that connects protein kinase to intracellular locations promoting cAMP related activation of PKA, which, in turn, enhances tau phosphorylation.[26]This process is one of the major findings in postmortem AD brains. Although only *ABCA7* was first identified using common variants in a GWAS.[27] The ATP-binding cassette, sub-family A, member 7 (*ABCA7*) gene, has both common risk variants with functional consequences and rare, damaging coding variants. *ABCA7* is a large gene with 47 exons encoding a transmembrane transporter protein. *ABCA7* is expressed in brain, especially in microglia, neurons, endothelial cells, pericytes where it may help degrade Aβ.[28] It may also have an important role in lipid metabolism. Common variants in *ABCA7* associated with AD have been observed in black and white, non-Hispanic individuals as well as in Hispanics.[27; 28] There have also been family data where premature termination codons have been found in *ABCA7.* [29]

ANK3 gene encodes for multiple isoforms of the scaffold protein, Ankyrin G, which is involved in protein interactions and neuronal functions. Mutations in ANK3 alter neuronal excitability and connectivity by altering ion channels and membrane proteins.[30] *ANK1* has found to be differentially methylated in AD. Several variants in *MYO15A*, which encodes a myosin involved in actin organization in mechanosensory hair bundles.[31] Actin is involved in retromer function which occurs in several neurodegenerative diseases including AD. SLC26A1 encodes a protein which acts as a transporter for ions and organic substrates [32] Variants in SLC26A1 may disrupt the function of the gene leading to oxidative stress, inflammation and metabolic dysfunction.[33]

Rare variants provide hypothesis free evidence for causality and can be targets for functional analyses to understand disease mechanisms.[23] Thus, while variants in several other AD genetic loci were less frequent, they are no less important. Several lines of evidence have implicated the angiotensin converting enzyme, *ACE* in AD.[34; 35] *ACE* encodes ACE-1, a rate-limiting enzyme in the cRAS pathway which generates disease-associated angiotensin II (Ang II) but also degrades and facilitates the clearance of Aβ. The gene encoding disintegrin-like and metalloproteinase with thrombospondin type 1 (*ADAMTS1*) is a member of the ADAMTS protein family. This family of genes are distinguished from *ADAM10* based on the number of copies of the thrombospondin 1-like repeats. Both are involved in extracellular matrix damage and repair.[36] *ADAMTS1* is thought to be involved in hydrolysis of APP and consequently decreases Aβ generation through inhibiting β-secretase-mediated cleavage. Clinically the gene may also affect cognitive ability by its effect on hippocampal amyloid processing. *CR1*, which encodes a complement receptor, regulating the complement cascade to clear cellular debris, including Aβ.[37] *ECHDC3* encodes an enzyme, enoyl CoA hydratase domain containing, and is a gene known to be involved in plasma lipids and other lipid related traits. Its expression is altered in the brains of patients with AD.[38] *EPHA1* belongs to the ephrin receptor subfamily of the protein-kinase family, and these receptors have been involved in development of the nervous system. In an early GWAS of AD, the Alzheimer's Disease Genetics Consortium identified a common variant in *EPHA1* associated with

ADGene Ontology annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity.[39] Variants in Neuronal Tyrosine Phosphorylated Phosphoinositide-3-Kinase Adaptor 1, *NYAP1*, appear to regulate immunoglobulin-like receptors beta and alpha (PILRB and PILRA), [40] but it is unclear how these variants contribute to AD pathogenesis. Presenilin 1, *PSEN1,* a gene associated with early onset AD, has been previously observed in late onset, fAD[41; 42] and it encodes the catalytic sub-unit of α-secretase involved in Aβ processing.

Variants in Protein Tyrosine Kinase 2 Beta**,** *PTK2B*, are thought to disrupt the normal suppression of tau phosphorylation and the effects of tauopathy thereby adding to the pathogenesis of AD.[43-45] Sortilin-related receptor with A-type repeats (SORLA or SORL1) is a sorting receptor in which variants impair processing of APP to soluble (s)APP and to the amyloid beta-peptide. SORL1 is also involved in endosomal degradation of Aβ and recycling in neurons.[24; 46] Finally, a common variant in signal peptide peptidase-like 2A*, SPPL2A,* was identified in a large genome wide array, and the gene is thought to be part of the immune response.[8; 47] We annotated the function of other genes with segregating variants in Table 2.

Rare variants have distinctive features, low likelihood of linkage disequilibrium with other variants in the region, more likely to affect gene function or expression, and a more direct role in diseases.[23] Efforts to discover associations driven by low-frequency, rare variants through genome sequencing efforts provide refinements to estimates of disease heritability.[48] Identifying rare variants in protein-coding regions through genome sequencing would also greatly facilitate annotating genes associated with complex disease and describing the functional consequences of human sequence variation.

The reduction in costs for genetic testing will also make it more feasible to include in genome or exome sequencing in clinical practice. Strategies to identify damaging variants will soon be in place and

clinicians and counselors will need to be able to identify and explain these results to patients and families. Families generally want to know the diagnostic relevance of our findings and the potential recurrence risk to other family. Therefore, a compelling argument can be made to accelerate efforts to identify rare variants in fAD because of the relative importance of turning these discoveries into meaningful clinical and biological progress.

Acknowledgements. The authors would like to thank the project managers at our respective sites for their efforts in recruitment and retention of these families.

Conflicts.

All of the authors receive funding from the National Institutes of Health. The following authors have no other relevant conflicts of interest to report: Tamil Iniyan Gunasekaran, Dolly Reyes-Dumeyer, Kelley M. Faber, Debby Tsuang, Diones Rivera Mejia, Martin Medrano, Rafael A. Lantigua, Margaret Pericak-Vance, Jonathan L. Haines, Robert Sweet, Carlos Cruchaga, Camille Alba, Clifton Dalgard, Tatiana Foroud, and Richard Mayeux.

Alison Goate receives money from Athena Diagnostics for licensing of TDP43mutations, and has consulted for UK Dementia Research Institute, UK VIB, Katholik University, Leuven, Belgium Center for Molecular Neurology, Antwerp, Belgium Queensland Brain Institute, Brisbane, Australia.

Brad Boeve receives honoraria for SAB activities for the Tau Consortium - funded by the Rainwater Charitable Foundation; research support for clinical trials sponsored by Alector, Biogen, Transposon, Cognition Therapeutics, and EIP Pharma; and research support from the Lewy Body Dementia Association, American Brain Foundation, Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, the Turner Family Foundation..

Roger Rosenberg receives funds from The Zale Foundation and receives license/royalty fees from Elsevier Publishing Inc., Springer Publishing Inc.; payments from Elsevier, Springer and Vitruvian, Inc., and The American Academy of Neurology; and he has a 2009 patent on an Amyloid Beta Gene vaccine.

Debby Tsuang receives consulting fees from Acadia Pharma.

David Bennett has consulting relationships with AbbVie Inc.

Funding

NIA AD-FBS: The National Institute on Aging Family Based Study supported the collection of samples used in this study through National Institute on Aging (NIA) grants U24AG026395, U24AG056270, and U24AG021886 (National Centralized Repository for Alzheimer's Disease).

EFIGA: Data collection for this project was supported by the Genetic Studies of Alzheimer's disease in Caribbean Hispanics (EFIGA) funded by the National Institute on Aging (NIA) and by the National Institutes of Health (NIH) (5R37AG015473, RF1AG015473, R56AG051876, R01 AG067501). The funders were not involved in the planning, the analyses, or the writing of this manuscript.

Consent Statement

NIA AD-FBS. Every institution was required to have their local Investigational Review Board and approve the consent form for this investigation. Thus, all individuals provided informed consent.

EFIGA. The Dominican Republic has a centralized Investigational Review Board. They approved the consent form used in this investigation for families living in the Dominican Republic. Thus, all individuals provided informed consent.

Key Words
Genome Wide Association Studies, gene loci; rare variants, familial Alzheimer's disease, genetic segregation

Figure 1

Legend Figure 1. A filtering process was described in the methods. To identify rare variants (gnomAD less than 1%), degree of segregation (complete vs incomplete). Segregation was defined as being present in all affected members of a family. If a variant segregated in one family and showed incomplete segregation in another family, we required a qualifying variant to be seen only in affected. Unaffected family members with qualifying variants were accepted if their age was five or more years below the age at onset of the affected carriers. **Incomplete segregation was defined as variants present in at least four affected individuals with AD in the specific cohort (AD-FBS or EFIGA), observed in more affected than unaffected individuals, and if present in unaffected individuals if their age was five or more years below the age at onset of the affected carriers.

Table 1a and 1b

Tables 1a and 1b. Distribution of participating families, age at onset and APOE-ε4 frequency.

1a. NIA AD-FBS	**Total families**	**Total participants**	**Affected**	**Unaffected**	**Age Affected**	**Age Unaffected**	**APOE-ε4 (%)**
Total Families	251	1055	594	461	75.19±8.03	71.61±9.72	0.38
Less than 2 affected	54	79	60	19	76.18±6.17	81±2.94	0.42
Greater than 2 affected	197	926	545	381	75.21±8.04	70.56±9.41	0.38
1b. EFIGA	**Total families**	**Total participants**	**Affected**	**Unaffected**	**Age Affected**	**Age Unaffected**	**APOE-ε4 (%)**
Total Families	271	1480	833	647	71.97±9.85	66.54±8.77	0.33
Less than 2 affected	57	435	145	290	80.25±8.66	81.28±6.76	0.27
Greater than 2 affected	214	1340	793	547	71.91±9.88	66.11±8.72	0.33

Table 2. Distribution of damaging missense and loss of function variants by cohort and variant type.

Gene		Cohort	Variant Type	Reference
ABCA1	chr9:104804721:C:G chr9:104798567:T:C chr9:104817343:G:A chr9:104819624:C:T chr9:104884475:G:A	AD-FBS EFIGA AD-FBS AD-FBS AD-FBS	LoF Missense Missense Missense Missense	Member of the superfamily of ATP-binding cassette transporters[49]
ABCA7	chr19:1057344:G:A chr19:1051965:C:T chr19:1044708:GGGGCACCTGGT:G	AD-FBS EFIGA EFIGA/ AD-FBS	Missense Missense LoF	Transmembrane transporter protein [39; 40]
ABI3	chr17:49217803:G:A	AD-FBS	Missense	Member of an adaptor protein family, also associated with Lewy Body disease[50]
ACE	chr17:63479054:G:C	EFIGA	Missense	Degradation and clearance of Aβ [51]
ADAM10	chr15:58717601:C:T	EFIGA	Missense	constitutive α-secretase processing of APP[52]
ADAMTS1	chr21:26838049:G:A chr21:26838216:C:T	AD-FBS EFIGA	Missense Missense	APP hydrolysis decreased Aβ [36]
ADAMTS20	chr12:43356572:T:C chr12:43428519:A:G	EFIGA EFIGA	Missense Missense	A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs[53]
AKAP9	chr7:91992989:G:C chr7:92097077:C:A chr7:92038422:A:G chr7:92040807:G:A chr7:92102769:G:A	AD-FBS AD-FBS EFIGA EFIGA EFIGA	Missense Missense Missense	Enhances tau phosphorylation[26]
ANK3	chr10:60070700:T:A chr10:60073965:T:C chr10:60074069:A:C chr10:60075299:G:A chr10:60186803:G:A	EFIGA EFIGA AD-FBS AD-FBS AD-FBS	Missense Missense Missense Missense Missense	Alters methylation dynamics associated with aging specifically in neurons[30]
BCKDK	chr16:31110471:C:T	EFIGA	Missense	Associated with obesity and expression of AD related genes[54]
CR1	chr1:207511589:C:T chr1:207523952:C:T	EFIGA EFIGA	Missense	Immune dysfunction and glial-mediated neuroinflammation[55]
CTSB	chr8:11847108:T:G	AD-FBS	Missense	Accumulates in amyloid plaques in human AD brain[56]
DOC2A	chr16:30010237:T:C	AD-FBS	LoF	Microglial regulator of CNS innate immunity found in AD[57]
ECHDC3	chr10:11742730:C:T	EFIGA	LoF	Enoyl-CoA Hydratase Domain Containing 3 involved in lipid metabolism[38]

EED	chr11:86245326:C:T chr11:86245267:C:T	EFIGA AD-FBS	Missense Missense	EED variants impact LTP, a measure of hippocampal memory function[58]
EPHA1	chr7:143398406:G:A chr7:143391696:G:A	AD-FBS EFIGA	Missense Missense	Eph/ephrin signaling disrupts alters activity at the blood brain barrier [59]
GPR141	chr7:37741061:C:A chr7:37741003:A:T	EFIGA AD-FBS	Missense Missense	Encodes an orphan receptor of the Class A rhodopsin-like G protein-coupled receptors[60]
HS3ST5	chr6:114057958:G:A	AD-FBS	Missense	Enhances the spread of tau pathology[61]
IDUA	chr4:987896:C:G	EFIGA/ AD-FBS	Missense Missense	Accumulation of glycosaminoglycans[62]
IL34	chr16:70654657:C:A	AD-FBS	LoF	Physiological role in clearance of cerebral amyloid β-protein[63]
LILRB2	chr19:54279530:T:A	EFIGA	Missense	LILRB2 antagonist antibody on microglial responses to amyloid plaques[64]
MYO15A	chr17:18120185:G:A chr17:18173824:G:A chr17:18119509:G:A chr17:18120434:C:T chr17:18133274:G:A chr17:18142122:G:A	EFIGA EFIGA AD-FBS AD-FBS AD-FBS AD-FBS	Missense Missense Missense Missense Missense Missense	Endosomal compartment disfunction[65]
NME8	chr7:37884404:G:T chr7:37896956:C:CA	EFIGA AD-FBS	LoF	Protective and antioxidant action[66]
NYAP1	chr7:100490675:C:T chr7:100488976:C:T	AD-FBS EFIGA	Missense Missense	Affects PILRB and PILRA immunoglobulin-like receptors[40]
PLCG2	chr16:81858323:C:T chr16:81923501:A:G	EFIGA AD-FBS	Missense Missense	Inflammatory response that is induced by amyloid plaques[67]
PRDM7	chr16:90060590:C:G chr16:90062060:A:G	AD-FBS	Missense	Transcription and other nuclear processes[68]
PRKD3	chr2:37289451:T:TG chr2:37289452:TACTC:T chr2:37289460:T:TTG	AD-FBS	LoF	Inflammatory signaling[69]
PSEN1	chr14:73170945:C:T chr14:73170959:A:G	AD-FBS EFIGA	Missense Missense	Subunit of γ-secretase [70]
PTK2B	chr8:27437198:G:A	EFIGA	Missense	Pyk2 suppresses Tau phosphorylation[71]
RBCK1	chr20:427337:C:T	AD-FBS	LoF	Heterologous ubiquitination [72]
SFRP4	chr7:37916317:C:T	EFIGA	Missense	Oxidative stress and inflammation[73]

SLC26A1	chr4:991652:G:A chr4:989768:G:A chr4:989896:A:G chr4:989305:G:A chr4:990080:G:A chr4:990241:C:T	AD-FBS EFIGA EFIGA AD-FBS AD-FBS AD-FBS	LoF Missense Missense Missense Missense Missense	Member sulfate/anion transporter gene family[32]
SNX1	chr15:64126203:C:T chr15:64131812:C:T	AD-FBS AD-FBS	Missense Missense	A member of the retromer complex[74]
SORL1	chr11:121604205:C:T	EFIGA	Missense	Endosomal degradation and recycling in neurons[46]
SPPL2A	chr15:50722170:A:T	AD-FBS	Missense	Involved in intramembrane cleavage of TMEM106B[75]
TNIP1	chr5:151052238:T:C	AD-FBS	Missense	Autoimmunity and tissue homeostasis via regulation of NFκB activation [76]
TPCN1	chr12:113293011:C:T chr12:113288795:G:A	EFIGA AD-FBS	Missense Missense	Lysosomal TPCN inhibition ameliorates Aβ pathology [77]
TREML2	chr6:41198273:C:A	EFIGA	Missense	Hyperphosphorylation and aggregation of tau and induces activation of microglia [78]
TSPOAP1	chr17:58307871:C:G chr17:58325608:C:T chr17:58327896:G:A	EFIGA EFIGA EFIGA	Missense	Phosphatidylglycerol-regulated functions[79]
UNC5CL	chr6:41033992:C:T	EFIGA	Missense	Differential methylation related to Aβ plaques[80]
USP6NL	chr10:11463631:G:A	AD-FBS	Missense	Acts as a GTPase-activating protein for Ras-related protein[81]
WDR81	chr17:1732823:G:A chr17:1728303:G:C	EFIGA AD-FBS	Missense Missense	Promotes the autophagic clearance of protein aggregates [82]

AD-FBS: Alzheimer's Disease - National Institute on Aging Family Based Study,
EFIGA: Estudio Familiar de la Genética de la Enfermedad.

Table 3

Table 3: Details of variants that are completely segregating in at least one family

Variant Type	Cohort	SNP	Gene	Families variant completely segregates	AD patients in families where the variant completely segregates	Healthy members in families where the variant completely segregates*	Co-segregates with APOE	AD GWAS index SNP	Family members that also carry the GWAS index SNP
Frameshift variant	EFIGA	chr19:1044708:GGGGCACCTGGT:G	*ABCA7*	2	8	2	No	chr19:1050875:A:G	2
Stop Gain		chr10:11742730:C:T	*ECHDC3*	1	3	0	No	chr10:11676714:A:G	3
Stop Gain		chr7:37884404:G:T	*NME8*	1	2	1	No	chr7:37844191:T:C	0
Frameshift Variant	AD-FBS	chr19:1044708:GGGGCACCTGGT:G	*ABCA7*	1	3	1	No	chr19:1050875:A:G	0
Frameshift Variant		chr7:37896956:C:CA	*NME8*	1	3	0	No	chr7:37844191:T:C	0
Splice Acceptor Variant		chr16:30010237:T:C	*DOC2A*	1	2	0	Yes	chr16:30010081:C:T	0
Structural Interaction Variant		chr16:70654657:C:A	*IL34*	2	5	2	Yes	chr16:70660097:C:A	0
Frameshift Variant		chr2:37289451:T:TG	*PRKD3*	1	2	1	No	chr2:37304796:T:C	0
Frameshift Variant		chr2:37289452:TACTC:T	*PRKD3*	1	2	1	No	chr2:37304796:T:C	0
Frameshift Variant		chr2:37289460:T:TTG	*PRKD3*	1	2	1	No	chr2:37304796:T:C	0
Stop Gain		chr20:427337:C:T	*RBCK1*	1	2	0	No	chr20:413334:A:G	2
Stop Gain		chr4:991652:G:A	*SLC26A1/ IDUA*	1	2	0	Yes		0
Splice Acceptor Variant		chr9:104804721:C:G	*ABCA1*	1	2	0	Yes	chr9:104903697:C:G	0
Damaging Missense (CADD>20)	EFIGA	chr19:1051965:C:T	*ABCA7*	1	2	4	No	chr19:1050875:A:G	1
		chr17:63479054:G:C	*ACE*	1	2	0	No	chr17:63471557:C:T	2
		chr15:58717601:C:T	*ADAM10*	1	2	2	No	chr15:58764824:T:A	4
		chr21:26838216:C:T	*ADAMTS1*	2	4	0	No	chr21:26775872:C:T	4
		chr12:43356572:T:C	*ADAMTS20*	1	5	3	No	chr12:43573874:T:G	0
		chr12:43428519:A:G	*ADAMTS20*	1	2	1	Yes	chr12:43573874:T:G	3
		chr7:92038422:A:G	*AKAP9*	1	2	0	No		

		chr7:92040807:G:A	*AKAP9*	1	2	0	No		
		chr7:92102769:G:A	*AKAP9*	1	2	0	No		
		chr1:207511589:C:T	*CR1*	1	2	1	Yes	chr1:207577223:T:C	3
		chr1:207523952:C:T	*CR1*	1	5	6	No	chr1:207577223:T:C	2
Damaging Missense (CADD>20)	EFIGA	chr7:143391696:G:A	*EPHA1*	1	2	3	No	chr7:143413669:G:A	3
		chr7:100488976:C:T	*NYAP1*	1	2	2	No	chr7:100494172:T:C	4
		chr14:73170959:A:G	*PSEN1*	1	5	1	No		
		chr8:27437198:G:A	*PTK2B*	1	2	0	No	chr8:27362470:C:T	0
		chr11:121604205:C:T	*SORL1*	1	3	0	Yes	chr11:121564878:T:C	0
		chr4:987896:C:G	*IDUA*	1	2	0	No	chr4:993555:G:T	0
		chr4:989768:G:A	*SLC26A1/ IDUA*	1	2	0	No	chr4:993555:G:T	0
		chr4:989896:A:G	*SLC26A1/ IDUA*	1	3	0	No	chr4:993555:G:T	0
		chr6:41033992:C:T	*UNC5CL*	1	3	0	No	chr6:41036354:G:A	0
		chr6:41198273:C:A	*TREML2*	1	4	1	No	chr6:41181270:A:G	0
		chr7:37741061:C:A	*GPR141/E PDR1*	1	2	0	Yes	chr7:37844191:T:C	2
		chr7:37916317:C:T	*SFRP4/E PDR1*	1	2	0	No	chr7:37844191:T:C	2
		chr9:104798567:T:C	*ABCA1*	1	3	0	Yes	chr9:104903697:C:G	3
		chr10:60070700:T:A	*ANK3*	1	2	1	Yes	chr10:60025170:T:G	2
		chr10:60073965:T:C	*ANK3*	1	3	0	No	chr10:60025170:T:G	0
		chr11:86245326:C:T	*EED*	1	3	0	No	chr11:86157598:T:C	3
		chr12:113293011:C:T	*TPCN1*	1	3	0	No	chr12:113281983:T:C	3
		chr16:31110471:C:T	*BCKDK*	1	2	0	No	chr16:31111250:C:T	0
		chr16:81858323:C:T	*PLCG2*	1	2	0	No	chr16:81908423:C:G	0
		chr17:1732823:G:A	*WDR81*	1	4	0	No	chr17:1728046:TGAG :T	0
		chr17:18120185:G:A	*MYO15A*	1	3	0	No	chr17:18156140:G:A	0
		chr17:18173824:G:A	*MYO15A*	1	2	0	No	chr17:18156140:G:A	0
		chr17:58307871:C:G	*TSPOAP1*	1	4	1	No	chr17:58332680:A:G	3
		chr17:58325608:C:T	*TSPOAP1*	1	4	0	Yes	chr17:58332680:A:G	0
		chr17:58327896:G:A	*TSPOAP1*	1	2	2	No	chr17:58332680:A:G	2
		chr19:54279530:T:A	*LILRB2*	1	2	0	No	chr19:54267597:C:T	1
Damaging Missense (CADD>20)	AD-FBS	chr19:1057344:G:A	*ABCA7*	2	5	4	No	chr19:1050875:A:G	6
		chr21:26838049:G:A	*ADAMTS1*	1	4	2	No	chr21:26775872:C:T	6

		chr7:91992989:G:C	*AKAP9*	1	2	0	Yes		
		chr7:92097077:C:A	*AKAP9*	1	3	2	No		
		chr7:143398406:G:A	*EPHA1*	1	3	1	No	chr7:143402040:C:A	2
		chr7:100490675:C:T	*NYAP1*	1	2	6	No	chr7:100494172:T:C	1
		chr14:73170945:C:T	*PSEN1*	1	2	0	No		
		chr15:50722170:A:T	*SPPL2A*	1	4	0	No	chr15:50716490:T:C	4
		chr4:987896:C:G	*IDUA*	1	2	0	No	chr4:993555:G:T	0
		chr4:989305:G:A	*SLC26A1/ IDUA*	1	2	1	No	chr4:993555:G:T	0
		chr4:990080:G:A	*SLC26A1/ IDUA*	1	2	0	No	chr4:993555:G:T	0
		chr4:990241:C:T	*SLC26A1/ IDUA*	1	2	0	No	chr4:993555:G:T	0
		chr7:37741003:A:T	*GPR141/E PDR1*	1	3	1	No	chr7:37844191:T:C	0
		chr9:104817343:G:A	*ABCA1*	1	3	1	No	chr9:104903697:C:G	4
		chr9:104819624:C:T	*ABCA1*	1	2	0	Yes	chr9:104903697:C:G	0
		chr9:104884475:G:A	*ABCA1*	1	2	0	No	chr9:104903697:C:G	0
		chr10:60074069:A:C	*ANK3*	1	3	0	Yes	chr10:60025170:T:G	3
		chr10:60075299:G:A	*ANK3*	1	2	1	Yes	chr10:60025170:T:G	1
		chr10:60186803:G:A	*ANK3*	1	2	0	Yes	chr10:60025170:T:G	2
		chr11:86245267:C:T	*EED*	1	3	4	Yes	chr11:86157598:T:C	3
		chr12:113288795:G:A	*TPCN1*	1	2	0	Yes	chr12:113281983:T:C	0
		chr16:81923501:A:G	*PLCG2*	1	2	0	No	chr16:81908423:C:G	0
		chr17:1728303:G:C	*WDR81*	1	2	0	Yes	chr17:1728046:TGAG :T	0
		chr17:18119509:G:A	*MYO15A*	1	2	0	No	chr17:18156140:G:A	2
		chr17:18120434:C:T	*MYO15A*	1	2	0	No	chr17:18156140:G:A	0
		chr17:18133274:G:A	*MYO15A*	1	2	1	No	chr17:18156140:G:A	0
		chr17:18142122:G:A	*MYO15A*	1	2	0	No	chr17:18156140:G:A	0
		chr10:11463631:G:A	*USP6NL*	1	2	0	Yes	chr10:11676714:A:G	0
		chr15:64126203:C:T	*SNX1*	1	3	1	No	chr15:64131307:G:A	1
		chr15:64131812:C:T	*SNX1*	1	2	0	Yes	chr15:64131307:G:A	0
		chr16:90060590:C:G	*PRDM7*	1	2	0	Yes	chr16:90103687:G:A	0
		chr16:90062060:A:G	*PRDM7*	1	3	0	Yes	chr16:90103687:G:A	3
		chr17:49217803:G:A	*ABI3*	1	2	0	Yes	chr17:49219935:T:C	0
		chr5:151052238:T:C	*TNIP1*	1	2	0	No	chr5:151052827:C:T	0

		chr6:114057958:G:A	*HS3ST5*	1	2	1	No	chr6:114291731:T:C	0
		chr8:11847108:T:G	*CTSB*	1	3	4	Yes	chr8:11844613:G:C	0

References

1. Alzheimer Association (2023). 2023 Alzheimer's disease facts and figures. Alzheimers Dement 19, 1598-1695.
2. Chartier-Harlin, M.C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., and Hardy, J. (1991). Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846.
3. Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., and James, L. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
4. Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
5. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C.E., Jondro, P.D., Schmidt, S.D., and Wang, K. (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
6. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., and Pericak-Vance, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
7. Pericak-Vance, M.A., Bebout, J.L., Gaskell, P.C., Jr., Yamaoka, L.H., Hung, W.Y., Alberts, M.J., Walker, A.P., Bartlett, R.J., Haynes, C.A., Welsh, K.A., et al. (1991). Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 48, 1034-1050.
8. Bellenguez, C., Kucukali, F., Jansen, I.E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A.C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022). New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412-436.
9. Khani, M., Gibbons, E., Bras, J., and Guerreiro, R. (2022). Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease. Mol Neurodegener 17, 3.
10. Qiao, M., Lee, A.J., Reyes-Dumeyer, D., Tosto, G., Faber, K., Goate, A., Renton, A., Chao, M., Boeve, B., Cruchaga, C., et al. (2023). Polygenic risk score penetrance & recurrence risk in familial Alzheimer disease. Ann Clin Transl Neurol 10, 744-756.
11. Reyes-Dumeyer, D., Faber, K., Vardarajan, B., Goate, A., Renton, A., Chao, M., Boeve, B., Cruchaga, C., Pericak-Vance, M., Haines, J.L., et al. (2022). The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. Alzheimers Dement 18, 1889-1897.
12. Romas, S.N., Santana, V., Williamson, J., Ciappa, A., Lee, J.H., Rondon, H.Z., Estevez, P., Lantigua, R., Medrano, M., Torres, M., et al. (2002). Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch Neurol 59, 87-91.
13. Vardarajan, B.N., Barral, S., Jaworski, J., Beecham, G.W., Blue, E., Tosto, G., Reyes-Dumeyer, D., Medrano, M., Lantigua, R., Naj, A., et al. (2018). Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer's disease. Ann Clin Transl Neurol 5, 406-417.
14. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
15. Morris, J.C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
16. Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123, 1-11.

17. Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8, 1-13.
18. Vardarajan, B.N., Faber, K.M., Bird, T.D., Bennett, D.A., Rosenberg, R., Boeve, B.F., Graff-Radford, N.R., Goate, A.M., Farlow, M., Sweet, R.A., et al. (2014). Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). JAMA Neurol 71, 315-323.
19. Ruiz-Grosso, P., Loret de Mola, C., Vega-Dienstmaier, J.M., Arevalo, J.M., Chavez, K., Vilela, A., Lazo, M., and Huapaya, J. (2012). Validation of the Spanish Center for Epidemiological Studies Depression and Zung Self-Rating Depression Scales: a comparative validation study. PLoS One 7, e45413.
20. Arora, K., Shah, M., Johnson, M., Sanghvi, R., Shelton, J., Nagulapalli, K., Oschwald, D.M., Zody, M.C., Germer, S., Jobanputra, V., et al. (2019). Deep whole-genome sequencing of 3 cancer cell lines on 2 sequencing platforms. Sci Rep 9, 19123.
21. Logue, M.W., Schu, M., Vardarajan, B.N., Farrell, J., Bennett, D.A., Buxbaum, J.D., Byrd, G.S., Ertekin-Taner, N., Evans, D., Foroud, T., et al. (2014). Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement 10, 609-618.e611.
22. Goswami, C., Chattopadhyay, A., and Chuang, E.Y. (2021). Rare variants: data types and analysis strategies. Ann Transl Med 9, 961.
23. Momozawa, Y., and Mizukami, K. (2021). Unique roles of rare variants in the genetics of complex diseases in humans. J Hum Genet 66, 11-23.
24. Holstege, H., van der Lee, S.J., Hulsman, M., Wong, T.H., van Rooij, J.G.J., Weiss, M., Louwersheimer, E., Wolters, F.J., Amin, N., Uitterlinden, A.G., et al. (2017). Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. European Journal of Human Genetics 25, 973-981.
25. Nordestgaard, L.T., Tybjaerg-Hansen, A., Nordestgaard, B.G., and Frikke-Schmidt, R. (2015). Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease. Alzheimers Dement 11, 1430-1438.
26. You, Y., Hersh, S.W., Aslebagh, R., Shaffer, S.A., Ikezu, S., Mez, J., Lunetta, K.L., Logue, M.W., Farrer, L.A., and Ikezu, T. (2022). Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells. Aging Cell 21, e13617.
27. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvina, V., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43, 429-435.
28. Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B.N., Wang, L.S., Valladares, O., Lin, C.F., Larson, E.B., Graff-Radford, N.R., et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 309, 1483-1492.
29. May, P., Pichler, S., Hartl, D., Bobbili, D.R., Mayhaus, M., Spaniol, C., Kurz, A., Balling, R., Schneider, J.G., and Riemenschneider, M. (2018). Rare ABCA7 variants in 2 German families with Alzheimer disease. Neurol Genet 4, e224.
30. Stevens, S.R., and Rasband, M.N. (2021). Ankyrins and neurological disease. Curr Opin Neurobiol 69, 51-57.
31. Moreland, Z.G., and Bird, J.E. (2022). Myosin motors in sensory hair bundle assembly. Curr Opin Cell Biol 79, 102132.

32. Remigante, A., Spinelli, S., Pusch, M., Sarikas, A., Morabito, R., Marino, A., and Dossena, S. (2022). Role of SLC4 and SLC26 solute carriers during oxidative stress. Acta Physiol (Oxf) 235, e13796.
33. Tirozzi, A., Quiccione, M.S., Cerletti, C., Donati, M.B., de Gaetano, G., Iacoviello, L., and Gialluisi, A. (2023). A Multi-Trait Association Analysis of Brain Disorders and Platelet Traits Identifies Novel Susceptibility Loci for Major Depression, Alzheimer's and Parkinson's Disease. Cells 12.
34. Farrer, L.A., Sherbatich, T., Keryanov, S.A., Korovaitseva, G.I., Rogaeva, E.A., Petruk, S., Premkumar, S., Moliaka, Y., Song, Y.Q., Pei, Y., et al. (2000). Association between angiotensin-converting enzyme and Alzheimer disease. Arch Neurol 57, 210-214.
35. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414-430.
36. Qiu, Y., Sha, L., Zhang, X., Li, G., Zhu, W., and Xu, Q. (2022). Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid-beta and consequent Alzheimer's disease risk. Front Aging Neurosci 14, 896522.
37. Fonseca, M.I., Chu, S., Pierce, A.L., Brubaker, W.D., Hauhart, R.E., Mastroeni, D., Clarke, E.V., Rogers, J., Atkinson, J.P., and Tenner, A.J. (2016). Analysis of the Putative Role of CR1 in Alzheimer's Disease: Genetic Association, Expression and Function. PLoS One 11, e0149792.
38. Yin, J., Feng, W., Yuan, H., Yuan, J., Wu, Y., Liu, X., Jin, C., and Cheng, Z. (2019). Association analysis of polymorphisms in STARD6 and near ECHDC3 in Alzheimer's disease patients carrying the APOE epsilon4 Allele. Neuropsychiatr Dis Treat 15, 213-218.
39. Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., Gallins, P.J., Buxbaum, J.D., Jarvik, G.P., Crane, P.K., et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43, 436-441.
40. Heath, L., Earls, J.C., Magis, A.T., Kornilov, S.A., Lovejoy, J.C., Funk, C.C., Rappaport, N., Logsdon, B.A., Mangravite, L.M., Kunkle, B.W., et al. (2022). Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Sci Rep 12, 6117.
41. Cruchaga, C., Haller, G., Chakraverty, S., Mayo, K., Vallania, F.L., Mitra, R.D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., et al. (2012). Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 7, e31039.
42. Lee, J.H., Kahn, A., Cheng, R., Reitz, C., Vardarajan, B., Lantigua, R., Medrano, M., Jimenez-Velazquez, I.Z., Williamson, J., Nagy, P., et al. (2014). Disease-related mutations among Caribbean Hispanics with familial dementia. Mol Genet Genomic Med 2, 430-437.
43. Beecham, G.W., Hamilton, K., Naj, A.C., Martin, E.R., Huentelman, M., Myers, A.J., Corneveaux, J.J., Hardy, J., Vonsattel, J.P., Younkin, S.G., et al. (2014). Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet 10, e1004606.
44. Brody, A.H., Nies, S.H., Guan, F., Smith, L.M., Mukherjee, B., Salazar, S.A., Lee, S., Lam, T.K.T., and Strittmatter, S.M. (2022). Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy. Mol Neurodegener 17, 32.
45. Fernandez, M.V., Budde, J., Del-Aguila, J.L., Ibanez, L., Deming, Y., Harari, O., Norton, J., Morris, J.C., Goate, A.M., group, N.-L.f.s., et al. (2018). Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. Front Neurosci 12, 209.
46. Mishra, S., Knupp, A., Szabo, M.P., Williams, C.A., Kinoshita, C., Hailey, D.W., Wang, Y., Andersen, O.M., and Young, J.E. (2022). The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human neurons. Cell Mol Life Sci 79, 162.

47. Li, Q.S., Tian, C., andMe Research, T., Hinds, D., and Seabrook, G.R. (2020). The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship. PLoS One 15, e0241552.
48. Kryukov, G.V., Shpunt, A., Stamatoyannopoulos, J.A., and Sunyaev, S.R. (2009). Power of deep, all-exon resequencing for discovery of human trait genes. Proc Natl Acad Sci U S A 106, 3871-3876.
49. Zarezade, V., Nazeri, Z., Azizidoost, S., Cheraghzadeh, M., Babaahmadi-Rezaei, H., and Kheirollah, A. (2024). Paradoxical effect of Abeta on protein levels of ABCA1 in astrocytes, microglia, and neurons isolated from C57BL/6 mice: an in vitro and in silico study to elucidate the effect of Abeta on ABCA1 in the brain cells. J Biomol Struct Dyn 42, 274-287.
50. Strickland, S.L., Morel, H., Prusinski, C., Allen, M., Patel, T.A., Carrasquillo, M.M., Conway, O.J., Lincoln, S.J., Reddy, J.S., Nguyen, T., et al. (2020). Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathol Commun 8, 172.
51. Zou, K., Maeda, T., Watanabe, A., Liu, J., Liu, S., Oba, R., Satoh, Y., Komano, H., and Michikawa, M. (2009). Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem 284, 31914-31920.
52. Yuan, X.Z., Sun, S., Tan, C.C., Yu, J.T., and Tan, L. (2017). The Role of ADAM10 in Alzheimer's Disease. J Alzheimers Dis 58, 303-322.
53. Nandadasa, S., Kraft, C.M., Wang, L.W., O'Donnell, A., Patel, R., Gee, H.Y., Grobe, K., Cox, T.C., Hildebrandt, F., and Apte, S.S. (2019). Secreted metalloproteases ADAMTS9 and ADAMTS20 have a non-canonical role in ciliary vesicle growth during ciliogenesis. Nat Commun 10, 953.
54. Charisis, S., Lin, H., Ray, R., Joehanes, R., Beiser, A.S., Levy, D., Seshadri, S., Sargurupremraj, M., and Satizabal, C.L. (2023). Obesity impacts the expression of Alzheimer's disease-related genes: The Framingham Heart Study. Alzheimers Dement 19, 3496-3505.
55. Zhu, X.C., Yu, J.T., Jiang, T., Wang, P., Cao, L., and Tan, L. (2015). CR1 in Alzheimer's disease. Mol Neurobiol 51, 753-765.
56. Hook, V., Yoon, M., Mosier, C., Ito, G., Podvin, S., Head, B.P., Rissman, R., O'Donoghue, A.J., and Hook, G. (2020). Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. Biochim Biophys Acta Proteins Proteom 1868, 140428.
57. Zhou, S., Ma, G., Luo, H., Shan, S., Xiong, J., and Cheng, G. (2023). Identification of 5 Potential Predictive Biomarkers for Alzheimer's Disease by Integrating the Unified Test for Molecular Signatures and Weighted Gene Coexpression Network Analysis. J Gerontol A Biol Sci Med Sci 78, 653-658.
58. Gockley, J., Montgomery, K.S., Poehlman, W.L., Wiley, J.C., Liu, Y., Gerasimov, E., Greenwood, A.K., Sieberts, S.K., Wingo, A.P., Wingo, T.S., et al. (2021). Multi-tissue neocortical transcriptome-wide association study implicates 8 genes across 6 genomic loci in Alzheimer's disease. Genome Med 13, 76.
59. Owens, H.A., Thorburn, L.E., Walsby, E., Moon, O.R., Rizkallah, P., Sherwani, S., Tinsley, C.L., Rogers, L., Cerutti, C., Ridley, A.J., et al. (2024). Alzheimer's disease-associated P460L variant of EphA1 dysregulates receptor activity and blood-brain barrier function. Alzheimers Dement 20, 2016-2033.
60. Caspers, S., Rockner, M.E., Jockwitz, C., Bittner, N., Teumer, A., Herms, S., Hoffmann, P., Nothen, M.M., Moebus, S., Amunts, K., et al. (2020). Pathway-Specific Genetic Risk for Alzheimer's Disease Differentiates Regional Patterns of Cortical Atrophy in Older Adults. Cereb Cortex 30, 801-811.
61. Ferreira, A., Royaux, I., Liu, J., Wang, Z., Su, G., Moechars, D., Callewaert, N., and De Muynck, L. (2022). The 3-O sulfation of heparan sulfate proteoglycans contributes to the cellular internalization of tau aggregates. BMC Mol Cell Biol 23, 61.

62. Wang, D., El-Amouri, S.S., Dai, M., Kuan, C.Y., Hui, D.Y., Brady, R.O., and Pan, D. (2013). Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U S A 110, 2999-3004.
63. Ho, A., Ngala, B., Yamada, C., Garcia, C., Duarte, C., Akkaoui, J., Ciolac, D., Nusbaum, A., Kochen, W., Efremova, D., et al. (2023). IL-34 exacerbates pathogenic features of Alzheimer's disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice. Biomed Pharmacother 166, 115435.
64. Zhao, P., Xu, Y., Jiang, L.L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.J., et al. (2022). LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol Neurodegener 17, 44.
65. Xicota, L., Lagarde, J., Eysert, F., Grenier-Boley, B., Rivals, I., Botte, A., Forlani, S., Landron, S., Gautier, C., Gabriel, C., et al. (2023). Modifications of the endosomal compartment in fibroblasts from sporadic Alzheimer's disease patients are associated with cognitive impairment. Transl Psychiatry 13, 54.
66. Liu, Y., Yu, J.T., Wang, H.F., Hao, X.K., Yang, Y.F., Jiang, T., Zhu, X.C., Cao, L., Zhang, D.Q., and Tan, L. (2014). Association between NME8 locus polymorphism and cognitive decline, cerebrospinal fluid and neuroimaging biomarkers in Alzheimer's disease. PLoS One 9, e114777.
67. Tsai, A.P., Dong, C., Lin, P.B., Messenger, E.J., Casali, B.T., Moutinho, M., Liu, Y., Oblak, A.L., Lamb, B.T., Landreth, G.E., et al. (2022). PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease. Genome Med 14, 17.
68. Blazer, L.L., Lima-Fernandes, E., Gibson, E., Eram, M.S., Loppnau, P., Arrowsmith, C.H., Schapira, M., and Vedadi, M. (2016). PR Domain-containing Protein 7 (PRDM7) Is a Histone 3 Lysine 4 Trimethyltransferase. J Biol Chem 291, 13509-13519.
69. McQuade, A., and Blurton-Jones, M. (2019). Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk. J Mol Biol 431, 1805-1817.
70. Kelleher, R.J., 3rd, and Shen, J. (2017). Presenilin-1 mutations and Alzheimer's disease. Proc Natl Acad Sci U S A 114, 629-631.
71. Salazar, S.V., Cox, T.O., Lee, S., Brody, A.H., Chyung, A.S., Haas, L.T., and Strittmatter, S.M. (2019). Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-beta-Induced Synaptic Dysfunction and Loss. J Neurosci 39, 758-772.
72. Sato, Y., Terawaki, S., Oikawa, D., Shimizu, K., Okina, Y., Ito, H., and Tokunaga, F. (2023). Involvement of heterologous ubiquitination including linear ubiquitination in Alzheimer's disease and amyotrophic lateral sclerosis. Front Mol Biosci 10, 1089213.
73. Zhang, J., Yang, Z., Liang, Z., Wang, M., Hu, C., Chang, C., Shi, L., Ji, Q., and Liu, L. (2022). Secreted frizzled-related protein 4 exerts anti-atherosclerotic effects by reducing inflammation and oxidative stress. Eur J Pharmacol 923, 174901.
74. Zhang, H., Huang, T., Hong, Y., Yang, W., Zhang, X., Luo, H., Xu, H., and Wang, X. (2018). The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases. Front Aging Neurosci 10, 79.
75. Brady, O.A., Zhou, X., and Hu, F. (2014). Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). J Biol Chem 289, 19670-19680.
76. Panyard, D.J., Reus, L.M., Ali, M., Liu, J., Deming, Y.K., Lu, Q., Kollmorgen, G., Carboni, M., Wild, N., Visser, P.J., et al. (2024). Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3. Alzheimers Dement.
77. Tong, B.C., Wu, A.J., Huang, A.S., Dong, R., Malampati, S., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S.G., Zhu, Z., Su, C., et al. (2022). Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease. Autophagy 18, 624-642.
78. Wang, S.Y., Gong, P.Y., E, Y., Zhang, Y.D., and Jiang, T. (2020). The Role of TREML2 in Alzheimer's Disease. J Alzheimers Dis 76, 799-806.

79. Suthar, S.K., Alam, M.M., Lee, J., Monga, J., Joseph, A., and Lee, S.Y. (2021). Bioinformatic Analyses of Canonical Pathways of TSPOAP1 and its Roles in Human Diseases. Front Mol Biosci 8, 667947.
80. Lang, A.L., Eulalio, T., Fox, E., Yakabi, K., Bukhari, S.A., Kawas, C.H., Corrada, M.M., Montgomery, S.B., Heppner, F.L., Capper, D., et al. (2022). Methylation differences in Alzheimer's disease neuropathologic change in the aged human brain. Acta Neuropathol Commun 10, 174.
81. Lopes, K.P., Snijders, G.J.L., Humphrey, J., Allan, A., Sneeboer, M.A.M., Navarro, E., Schilder, B.M., Vialle, R.A., Parks, M., Missall, R., et al. (2022). Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat Genet 54, 4-17.
82. Liu, X., Yin, L., Li, T., Lin, L., Zhang, J., and Li, Y. (2021). Reduction of WDR81 impairs autophagic clearance of aggregated proteins and cell viability in neurodegenerative phenotypes. PLoS Genet 17, e1009415.

Click here to access/download
Supplementary files
Supplementary Tables 1-3.xlsx

Figure 1. High impact (HI) coding and loss of function (LoF) variants identified in the AD-FBS and EFIGA Families.